1
|
Moraes de Farias K, Rosa-Ribeiro R, Souza EE, Kobarg J, Banwell MG, de Brito Vieira Neto J, Leyenne Alves Sales S, Roberto Ribeiro Costa P, Cavalcante Dos Santos R, Vilaça Gaspar F, Gomes Barreto Junior A, da Conceição Ferreira Oliveira M, Odorico de Moraes M, Libardi M Furtado C, Carvalho HF, Pessoa C. The Isoflavanoid (+)-PTC Regulates Cell-Cycle Progression and Mitotic Spindle Assembly in a Prostate Cancer Cell Line. Chem Biodivers 2022; 19:e202200102. [PMID: 35362194 DOI: 10.1002/cbdv.202200102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 03/31/2022] [Indexed: 12/24/2022]
Abstract
Prostate cancer is the second most common malignancy in men and the development of effective therapeutic strategies remains challenging when more advanced, androgen-independent or insensitive forms are involved. Accordingly, we have evaluated, using flow cytometry, confocal microscopy and image analysis, the anti-proliferative effects of (+)-2,3,9-trimethoxypterocarpan [(+)-PTC, 1] on relevant human prostate cancer cells as well as its capacity to control mitosis within them. In particular, the studies reported herein reveal that (+)-PTC exerts anti-proliferative activity against the PC-3 cell lines by regulating cell-cycle progression with mitosis being arrested in the prophase or prometaphase. Furthermore, it emerges that treatment of the target cells with this compound results in the formation of monopolar spindles, disorganized centrosomes and extensively disrupted γ-tubulin distributions while centriole replication remains unaffected. Such effects suggest (+)-PTC should be considered as a possible therapy for androgen-insensitive/independent prostate cancer.
Collapse
Affiliation(s)
- Kaio Moraes de Farias
- Programa de Pós-Graduação em Biotecnologia - RENORBIO - Rede Nordeste de Biotecnologia, Federal University of Ceará - UFC, 60020-181, Fortaleza, CE, Brazil.,Núcleo de Pesquisa e Desenvolvimento de Medicamentos - NPDM, Federal University of Ceará - UFC, Fortaleza, CE 60430-275, Brazil
| | - Rafaela Rosa-Ribeiro
- Department of Structural and Functional Biology, Biology Institute, State University of Campinas, Campinas, 13083-970, SP, Brazil
| | - Edmarcia E Souza
- Faculdade de Ciências Farmacêuticas, State University of Campinas, Campinas, 13083-859, SP, Brazil
| | - Jörg Kobarg
- Faculdade de Ciências Farmacêuticas, State University of Campinas, Campinas, 13083-859, SP, Brazil
| | - Martin G Banwell
- Institute for Advanced and Applied Chemical Synthesis, Jinan University, Guangzhou, 510632, China
| | - José de Brito Vieira Neto
- Núcleo de Pesquisa e Desenvolvimento de Medicamentos - NPDM, Federal University of Ceará - UFC, Fortaleza, CE 60430-275, Brazil
| | - Sarah Leyenne Alves Sales
- Núcleo de Pesquisa e Desenvolvimento de Medicamentos - NPDM, Federal University of Ceará - UFC, Fortaleza, CE 60430-275, Brazil
| | - Paulo Roberto Ribeiro Costa
- Laboratório de Química Bioorgânica (LQB), Instituto de Pesquisas de Produtos Naturais, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-909, RJ, Brazil
| | - Rafael Cavalcante Dos Santos
- Engenharia de Processos Químicos e Bioquímicos (EPQB), Escola de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-909, RJ, Brazil
| | - Francisco Vilaça Gaspar
- Laboratório de Química Bioorgânica (LQB), Instituto de Pesquisas de Produtos Naturais, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-909, RJ, Brazil
| | - Amaro Gomes Barreto Junior
- Engenharia de Processos Químicos e Bioquímicos (EPQB), Escola de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-909, RJ, Brazil
| | | | - Manoel Odorico de Moraes
- Núcleo de Pesquisa e Desenvolvimento de Medicamentos - NPDM, Federal University of Ceará - UFC, Fortaleza, CE 60430-275, Brazil
| | - Cristiana Libardi M Furtado
- Núcleo de Pesquisa e Desenvolvimento de Medicamentos - NPDM, Federal University of Ceará - UFC, Fortaleza, CE 60430-275, Brazil.,Experimental Biology Center - NUBEX, University of Fortaleza, UNIFOR, Fortaleza, CE 60811-905, Brazil
| | - Hernandes F Carvalho
- Department of Structural and Functional Biology, Biology Institute, State University of Campinas, Campinas, 13083-970, SP, Brazil
| | - Claudia Pessoa
- Programa de Pós-Graduação em Biotecnologia - RENORBIO - Rede Nordeste de Biotecnologia, Federal University of Ceará - UFC, 60020-181, Fortaleza, CE, Brazil.,Núcleo de Pesquisa e Desenvolvimento de Medicamentos - NPDM, Federal University of Ceará - UFC, Fortaleza, CE 60430-275, Brazil
| |
Collapse
|
2
|
Paier CRK, Maranhão SS, Carneiro TR, Lima LM, Rocha DD, da Silva Santos R, de Farias KM, de Moraes-Filho MO, Pessoa C. Natural products as new antimitotic compounds for anticancer drug development. Clinics (Sao Paulo) 2018; 73:e813s. [PMID: 30540125 PMCID: PMC6256996 DOI: 10.6061/clinics/2018/e813s] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 10/09/2018] [Indexed: 12/19/2022] Open
Abstract
Cell cycle control genes are frequently mutated in cancer cells, which usually display higher rates of proliferation than normal cells. Dysregulated mitosis leads to genomic instability, which contributes to tumor progression and aggressiveness. Many drugs that disrupt mitosis have been studied because they induce cell cycle arrest and tumor cell death. These antitumor compounds are referred to as antimitotics. Vinca alkaloids and taxanes are natural products that target microtubules and inhibit mitosis, and their derivatives are among the most commonly used drugs in cancer therapy worldwide. However, severe adverse effects such as neuropathies are frequently observed during treatment with microtubule-targeting agents. Many efforts have been directed at developing improved antimitotics with increased specificity and decreased likelihood of inducing side effects. These new drugs generally target specific components of mitotic regulation that are mainly or exclusively expressed during cell division, such as kinases, motor proteins and multiprotein complexes. Such small molecules are now in preclinical studies and clinical trials, and many are products or derivatives from natural sources. In this review, we focused on the most promising targets for the development of antimitotics and discussed the advantages and disadvantages of these targets. We also highlighted the novel natural antimitotic agents under investigation by our research group, including combretastatins, withanolides and pterocarpans, which show the potential to circumvent the main issues in antimitotic therapy.
Collapse
Affiliation(s)
- Carlos Roberto Koscky Paier
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- *Corresponding author. E-mail:
| | - Sarah Sant'Anna Maranhão
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Teiliane Rodrigues Carneiro
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
- Laboratorio de Avaliacao e Sintese de Substancias Bioativas (LASSBio), Instituto de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BR
| | - Lídia Moreira Lima
- Laboratorio de Avaliacao e Sintese de Substancias Bioativas (LASSBio), Instituto de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BR
| | - Danilo Damasceno Rocha
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Renan da Silva Santos
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Kaio Moraes de Farias
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Manoel Odorico de Moraes-Filho
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Claudia Pessoa
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
| |
Collapse
|